8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      B Cells as a Therapeutic Target in Paediatric Rheumatic Disease

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          B cells carry out a central role in the pathogenesis of autoimmune disease. In addition to the production of autoantibodies, B cells can contribute to disease development by presenting autoantigens to autoreactive T cells and by secreting pro-inflammatory cytokines and chemokines which leads to the amplification of the inflammatory response. Targeting both the antibody-dependent and antibody-independent function of B cells in adult rheumatic disease has led to the advent of B cell targeted therapies in clinical practice. To date, whether B cell depletion could also be utilized for the treatment of pediatric disease is relatively under explored. In this review, we will discuss the role of B cells in the pathogenesis of the pediatric rheumatic diseases Juvenile Idiopathic Arthritis (JIA), Juvenile Systemic Lupus Erythematosus (JSLE) and Juvenile Dermatomyositis (JDM). We will also explore the rationale behind the use of B cell-targeted therapies in pediatric rheumatic disease by highlighting new case studies that points to their efficacy in JIA, JSLE, and JDM.

          Related collections

          Most cited references75

          • Record: found
          • Abstract: found
          • Article: not found

          Effector and regulatory B cells: modulators of CD4+ T cell immunity.

          B cells are essential for humoral immunity, but the role that they have in regulating CD4(+) T cell responses remains controversial. However, new data showing that the transient depletion of B cells potently influences the induction, maintenance and reactivation of CD4(+) T cells, with the recent identification of antibody-independent functions of B cells, have reinvigorated interest in the many roles of B cells in both infectious and autoimmune diseases. In this Review, we discuss recent data showing how effector and regulatory B cells modulate CD4(+) T cell responses to pathogens and autoantigens.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Reciprocal regulation of polarized cytokine production by effector B and T cells.

            Although B cells produce cytokines it is not known whether B cells can differentiate into effector subsets that secrete polarized arrays of cytokines. We have identified two populations of "effector" B cells (Be1 and Be2) that produce distinct patterns of cytokines depending on the cytokine environment in which the cells were stimulated during their primary encounter with antigen and T cells. These effector B cell subsets subsequently regulate the differentiation of naïve CD4+ T cells to TH1 and TH2 cells through production of polarizing cytokines such as interleukin 4 and interferon gamma. In addition, Be1 and Be2 cells could be identified in animals that were infected with pathogens that preferentially induce a Type 1 and Type 2 immune response. Together these results suggest that, in addition to their well defined role in antibody production, B cells may regulate immune responses to infectious pathogens through their production of cytokines.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              B cells responses and cytokine production are regulated by their immune microenvironment.

              The adaptive immune system consists of two types of lymphocytes: T and B cells. These two lymphocytes originate from a common precursor, yet are fundamentally different with B cells mediating humoral immunity while T cells mediate cell mediated immunity. In cytokine production, naïve T cells produce multiple cytokines upon activation while naïve activated B cells do not. B cells are capable of producing cytokines, but their cytokine production depends on their differentiation state and activation conditions. Hence, unlike T cells that can produce a large amount of cytokines upon activation, B cells require specific differentiation and activation conditions to produce cytokines. Many cytokines act on B cells as well. Here, we discuss several cytokines and their effects on B cells including: Interleukins, IL-7, IL-4, IL-6, IL-10, and Interferons, IFN-α, IFN-β, IFN-γ. These cytokines play important roles in the development, survival, differentiation and/or proliferation of B cells. Certain chemokines also play important roles in B cell function, namely antibody production. As an example, we discuss CCL28, a chemokine that directs the migration of plasma cells to mucosal sites. We conclude with a brief overview of B cells as cytokine producers and their likely functional consequences on the immune response.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                14 February 2019
                2019
                : 10
                : 214
                Affiliations
                [1] 1Infection, Immunity, Inflammation Programme, UCL Great Ormond Street Institute of Child Health , London, United Kingdom
                [2] 2Arthritis Research UK Centre for Adolescent Rheumatology, University College London, UCLH and GOSH , London, United Kingdom
                [3] 3NIHR Biomedical Research Centre, Great Ormond Street Hospital , London, United Kingdom
                Author notes

                Edited by: Abbe N. de Vallejo, University of Pittsburgh, United States

                Reviewed by: Zoltan Jakus, Semmelweis University, Hungary; Marko Radic, University of Tennessee College of Medicine, United States

                *Correspondence: Elizabeth C. Rosser e.rosser@ 123456ucl.ac.uk

                This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2019.00214
                6382733
                30837988
                104830b1-194d-43ea-8246-19d91036b80c
                Copyright © 2019 Wilkinson and Rosser.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 12 November 2018
                : 24 January 2019
                Page count
                Figures: 3, Tables: 1, Equations: 0, References: 111, Pages: 14, Words: 11916
                Funding
                Funded by: Arthritis Research UK 10.13039/501100000341
                Funded by: National Institute for Health Research 10.13039/501100000272
                Categories
                Immunology
                Review

                Immunology
                b cells,autoimmunity,pediatric autoimmune diseases,inflammation,biologics
                Immunology
                b cells, autoimmunity, pediatric autoimmune diseases, inflammation, biologics

                Comments

                Comment on this article